Navigation Links
Peregrine Pharmaceuticals Reports 61% Objective Response Rate in 46-Patient Bavituximab Phase II Trial in Advanced Breast Cancer
Date:10/21/2009

nths, a promising early result. Patient follow-up in the trial is continuing.

"The data released today continues to reinforce the positive results seen across the five cancer trials to date assessing the potential of bavituximab in different treatment combinations across multiple tumor types," said Steven W. King, president and CEO of Peregrine. "We believe this data in aggregate shows the broad potential of this novel therapeutic compound for the treatment of solid tumors. We look forward to reporting further results from our ongoing bavituximab studies and to providing more details on future clinical development plans as they are finalized over the coming months."

Secondary objectives of the study include measuring time to tumor progression, duration of response, overall patient survival and safety parameters. Patients in the study are evaluated regularly for tumor response according to RECIST criteria. Patients may continue to receive bavituximab as monotherapy after completion of chemotherapy as long as the cancer does not progress and side effects are acceptable.

The World Health Organization reports that breast cancer is the most commonly diagnosed cancer in women and is second only to lung cancer as a leading cause of female cancer deaths. The National Cancer Institute estimates that approximately 192,370 U.S. women will be diagnosed with breast cancer in 2009 and 40,170 women will die of the disease in the U.S. alone.

Bavituximab is a monoclonal antibody that targets the cellular membrane component phosphatidylserine (PS) that is usually located inside cells, but which becomes exposed on the outside of the cells that line the blood vessels of tumors, creating a specific target for anti-cancer treatments. Bavituximab acts by binding to externalized PS on tumor blood vessels and inducing immune cell-mediated destruction of these blood vessels. It also restores the immune system's ability to recognize and resp
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Pharmaceuticals Appoints Former Genentech Senior Executive Dr. Robert Garnick as Head of Regulatory Affairs
2. Peregrine Pharmaceuticals Forms Anti-Viral Research Group to Oversee Its Anti-PS Infectious Disease Collaborations
3. Interim Phase II Data Presented at XIV World Congress of Neurological Surgery Supports Potential of Peregrines Cotara(R) for Treatment of Brain Cancer
4. Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials
5. Peregrine Pharmaceuticals Completes Patient Enrollment in its Phase II Trial of Bavituximab Plus Docetaxel in Breast Cancer Patients
6. Affitech-Discovered Anti-PS Antibodies in Development by Peregrine Pharmaceuticals Show Excellent Functionality in Preclinical Studies
7. Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrines Fully Human Anti-PS Antibody in Prostate Cancer Model
8. Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrines PS-Targeting Antibodies
9. Peregrine Pharmaceuticals Reports Positive Preliminary Data From Phase II Bavituximab Lung Cancer Trial
10. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial
11. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... KANSAS CITY, Kan. , Dec. 18, 2014 ... PETX ), a biopharmaceutical company focused on ... for companion animals, today announced positive results from ... company,s innovative drug for treating pain in dogs ... demonstrated improvements in pain assessment scores that were ...
(Date:12/17/2014)... and SAN DIEGO , Dec. 17, 2014 ... ; AEX: PHIA) and Volcano Corporation (NASDAQ: VOLC ... for cardiovascular applications, today announced that they have entered into ... commence a tender offer to acquire all of the issued ... or a total equity purchase price of USD 1 billion ...
(Date:12/17/2014)... , Dec. 17, 2014  Strategic Health Services, Inc. ... solutions, today announced a strategic agreement with QualCare, Inc., a ... New Jersey regional marketplace.  This agreement will ... health and wellness solutions QualCare brings to its clients ... surrounding region. QualCare plans cover more ...
Breaking Medicine Technology:Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5Philips to acquire Volcano to expand global leadership position in image-guided therapy market 2Philips to acquire Volcano to expand global leadership position in image-guided therapy market 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 4Philips to acquire Volcano to expand global leadership position in image-guided therapy market 5Philips to acquire Volcano to expand global leadership position in image-guided therapy market 6Philips to acquire Volcano to expand global leadership position in image-guided therapy market 7Philips to acquire Volcano to expand global leadership position in image-guided therapy market 8Strategic Health Services to collaborate with QualCare on Population Health and Wellness Technology for QualCare Members 2Strategic Health Services to collaborate with QualCare on Population Health and Wellness Technology for QualCare Members 3
... 2012  InterMune, Inc. (NADSAQ: ITMN) today reported ... announced its decision granting the additional benefit ... treatment of mild-to-moderate idiopathic pulmonary fibrosis (IPF).  ... 4 (not quantifiable benefit)  in the rating ...
... March 15, 2012 Reportlinker.com announces that ... in its catalogue: ... http://www.reportlinker.com/p0578259/Vaccines---Asia.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This market research report ... actual market situation, trends and future outlook ...
Cached Medicine Technology:Esbriet® (pirfenidone) Benefit Granted by German Federal Joint Committee (G-BA) 2Esbriet® (pirfenidone) Benefit Granted by German Federal Joint Committee (G-BA) 3Esbriet® (pirfenidone) Benefit Granted by German Federal Joint Committee (G-BA) 4Esbriet® (pirfenidone) Benefit Granted by German Federal Joint Committee (G-BA) 5Esbriet® (pirfenidone) Benefit Granted by German Federal Joint Committee (G-BA) 6Vaccines - Asia 2
(Date:12/19/2014)... The print component of Vision and Hearing is ... Toronto Star, with a circulation of approximately 230,433 copies ... is distributed nationally through a vast social media strategy ... partner outlets. To explore the digital version of the ... an exclusive interview with Mark DeMontis , sharing ...
(Date:12/19/2014)... Potentially illness-causing E. coli bacteria were found on nearly ... a new study. Researchers checked cilantro, basil and ... in Los Angeles and Orange counties in California, and ... tested, 24 percent were positive for E. coli. One ... Both types of bacteria can cause sometimes serious ...
(Date:12/19/2014)... 2014 (HealthDay News) -- Older adults who have lost all ... than people who still have at least some of their ... total tooth loss could provide an early warning of increased ... British researchers said. However, the findings don,t prove that ... study included more than 3,100 participants 60 and older. People ...
(Date:12/19/2014)... LENEXA, Kan. (PRWEB) December 19, 2014 ... dedicated exclusively to healthcare providers, has been retained to ... for Estes Park Medical Center in Estes Park, Colo. ... B. E. Smith has recently placed more than 900 ... Center (EPMC) is a 25-bed, not-for-profit critical access hospital ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 Hands On Mobile ... available. The Spa On Wheels has been transformed into ... from the outside world seems to disappear. The Virtual Tour ... massages, facials, spa parties, corporate events and more. , The ... Spa On Wheels which is actually an overhauled Winnebago. Marla ...
Breaking Medicine News(10 mins):Health News:Mark DeMontis, Founder of Courage Canada, shares his passion for bringing hockey to those affected by blindness in Mediaplanet’s “Vision and Hearing” campaign 2Health News:E. Coli Germs Found on Farmers Market Herbs 2Health News:Loss of Teeth Linked to Physical, Mental Decline in Study 2Health News:Estes Park Medical Center Retains B. E. Smith to Recruit New Chief Financial Officer 2Health News:Estes Park Medical Center Retains B. E. Smith to Recruit New Chief Financial Officer 3Health News:A Virtual Tour Of Hands On Mobile Massage Spa Is Now Available 2Health News:A Virtual Tour Of Hands On Mobile Massage Spa Is Now Available 3
... of British Columbia have identified new breast cancer genes ... and form the basis of next-generation treatments. Researchers ... based on the genetic fingerprint of a tumour. Many ... cancer biology, allowing doctors to predict whether a tumour ...
... and quality-of-life issues should be considered essential elements of ... point of breast cancer diagnosis. However, for women suffering ... other medically underserved areas around the world, this fundamental ... To address these issues, many of the world,s ...
... HealthDay Reporter , TUESDAY, April 17 (HealthDay News) ... they enter the Part D "donut hole," the seniors ... essential for heart health, new research shows. "We looked ... three and half months during a year. While we didn,t ...
... Carina Storrs HealthDay Reporter , TUESDAY, April 17 ... could one day help diagnose teens with depression. To ... depression. Then they tested the markers in a small group ... distinguish the teens with major depression from those without depression. ...
... , HOUSTON - Scientists who developed a technology for identifying ... surface have found a way to penetrate the outer membrane ... inside the cell. In a paper published today online ... at The University of Texas MD Anderson Cancer Center reports ...
... , , , , , ... AUDIO: New research in half siblings adds to evidence that even though autism is far ... Click here for more information. , , , ... , , , , , , ...
Cached Medicine News:Health News:Scientists rewrite rulebook on breast cancer in landmark global study 2Health News:Scientists rewrite rulebook on breast cancer in landmark global study 3Health News:International breast health global summit will focus on supportive care and quality of life 2Health News:International breast health global summit will focus on supportive care and quality of life 3Health News:Seniors Stop Taking Heart Drugs In Medicare 'Donut Hole' 2Health News:Seniors Stop Taking Heart Drugs In Medicare 'Donut Hole' 3Health News:Researchers Develop Blood Test for Depression 2Health News:Researchers Develop Blood Test for Depression 3Health News:Scientists tailor cell surface targeting system to hit organelle ZIP codes 2Health News:Scientists tailor cell surface targeting system to hit organelle ZIP codes 3Health News:Study of half siblings provides genetic clues to autism 2Health News:Study of half siblings provides genetic clues to autism 3Health News:Study of half siblings provides genetic clues to autism 4Health News:Study of half siblings provides genetic clues to autism 5
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: